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Abstract
This is the first study to investigate the effect of vitamin D receptor (VDR) gene single-nucleotide polymorphisms on the
clinicopathologic features of papillary thyroid cancer in Turkey. A total of 165 patients with papillary thyroid cancer and
172 controls were included in this case–control study. VDR gene single-nucleotide polymorphisms FokI (rs2228570),
BsmI (rs1544410), ApaI (rs7975232), and TaqI (rs731236) were evaluated using reverse-transcription polymerase chain
reaction. VDR gene polymorphisms BsmI, ApaI, and TaqI did not differ between the papillary thyroid cancer group and
control group (p. 0.05, each). BsmI, ApaI, and TaqI were not associated with papillary thyroid cancer risk. The VDR
gene FokI CT/TT genotype was associated with an increased papillary thyroid cancer risk (CT vs CC: odds ratio = 1.71,
95% confidence interval = 1.15–2.76, p = 0.028; TT vs CC: odds ratio = 2.44, 95% confidence interval = 1.29–4.62,
p = 0.005; CT/TT vs CC: odds ratio = 1.88, 95% confidence interval = 1.20–2.96, p = 0.006; CT/CC vs TT: odds
ratio = 1.80, 95% confidence interval = 1.05–3.20, p = 0.041). VDR gene polymorphisms were not in linkage
disequilibrium. The FokI TT genotype was associated with having T3 and T4, stage III/IV, extra-thyroidal invasion. The
FokI CT/TTor TT genotype was associated with developing N1 status, multifocality, tumor size ø 10mm, and treatment
with radioiodine therapy. Persistence/recurrence did not differ between the FokI genotypes. Carriers of the FokI T allele
were at an increased risk of more advanced tumor-node-metastasis stage, greater tumor size, multifocality, and extra-
thyroidal invasion of papillary thyroid cancer compared with the CC genotype. VDR gene FokI T allele and TT genotype
correlated with aggressiveness of papillary thyroid cancer; thus, FokI could be useful as a poor prognostic factor to
assess the high risk of papillary thyroid cancer.
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Introduction
Thyroid cancer is a relatively rare neoplasm that affects
an estimated 14.9 people per 100,000. It is the most
common endocrine cancer and constituted predomi-
nantly of its papillary subtype. Thyroid cancer accounts
for \2% of all cancers in males and 1%–1.5% in
females with a female-to-male ratio of 3:1 in almost all
ethnic groups.1,2 Genetic variation contributes to the
development of thyroid cancer; however, the pathogen-
esis of thyroid cancer is not yet known exactly.2,3
1Department of Endocrinology and Metabolism, Ankara Diskapi Yildirim
Beyazit Teaching and Research Hospital, Ankara, Turkey
2Department of Medical Biology, Basxkent University, Ankara, Turkey
3Department of Endocrinology and Metabolism, Afyonkarahisar Saglik
Bilimleri University, Afyonkarahisar, Turkey
4Department of Genetic Research, Ankara Diskapi Yildirim Beyazit
Teaching and Research Hospital, Ankara, Turkey
Corresponding author:
Selvihan Beysel, Department of Endocrinology and Metabolism,
Afyonkarahisar Saglik Bilimleri University, Afyonkarahisar 03200, Turkey.
Email: beyselselvihan@gmail.com
Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial
use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and
Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Molecular biomarkers have not been identified for the
diagnosis and prognosis of thyroid cancer.4
In addition to the effect on calcium and bone hemos-
tasis, 1,25-diydroxyvitamin D3 (1,25(OH)2D3), the
biologically active form of vitamin D, has many extra-
skeletal effects such as anti-proliferative, anti-apoptotic,
and pro-differentiation properties.5–7 Active vitamin D
shows its biologic actions by tightly binding to the
intracellular vitamin D receptor (VDR), a hormone-
regulated transcription factor. VDR is a member of the
nuclear hormone receptor family of transacting tran-
scriptional regulatory factors, including the steroid hor-
mone receptors, thyroid hormone receptors, retinoic
acid receptors, and retinoid-X receptors. The VDR gene
is located on chromosome 12q13.1 and is composed of
five promoters, eight coding exons, and six untranslated
exons.5–8 Its promoter region is able to generate multi-
ple transcripts. During activation, VDR forms a hetero-
dimer with the related retinoid-X receptor and regulates
the expression of many target genes because it binds to
the vitamin D response elements in the chromatin
region. Active vitamin D regulates gene transcription
by binding to the VDR. It shows anti-tumoral effect by
stimulating differentiation and apoptosis.9 It reduces
cellular proliferation, inflammation, angiogenesis, and
invasion. VDR regulates other metabolic pathways
such as immune response and cancer signaling.5–10
These are considered as VDR-mediated signaling path-
ways. Studies have shown that VDR gene polymorph-
isms are found in patients with cancer.11Bsml (A.G,
rs1544410), ApaI (A.C, rs7975232), TaqI (T.C,
rs731236), and FokI (C.T, rs2228570) are human VDR
gene polymorphisms. VDR BsmI, ApaI, and FokI gene
polymorphisms have shown to increase the risk of hav-
ing breast cancer.12VDR FokI gene polymorphism
increases the susceptibility for prostate cancer, BsmI
polymorphism does so for malignant melanoma, and
TaqI increases the risk for renal cell carcinoma.11 The
FokI polymorphism was associated with an increased
ovarian cancer risk.13FokI T/T genotype was associ-
ated with higher progression rate in head and neck
squamous cell carcinoma.14VDR BsmI polymorphism
was a risk factor for colorectal and skin cancer in a
Caucasian population and the ApaI polymorphism
was a risk factor for basal cell cancer in an Asian pop-
ulation. The TaqI polymorphism was a risk factor for
oral, breast, and basal cell cancer, and the FokI poly-
morphism was a risk factor for ovarian and skin can-
cer.15 However, to date, the association between the
VDR gene polymorphism and thyroid cancer has only
been investigated in two studies. The VDR ApaI CC
and FokI TT polymorphisms were associated with
decreased follicular thyroid cancer but haplotype
Tabf was associated with an increased risk for follicu-
lar thyroid cancer.10 The VDR gene polymorphism
was not associated with differentiated thyroid
cancer.16
This study aimed to investigate the relation between
the VDR gene polymorphism and the clinical features
and prognostic significance of patients with papillary
thyroid cancer (PTC) in a Turkish population. This is
the first study to investigate the effects of VDR gene
polymorphisms on the clinical features of PTC includ-
ing cancer staging, outcomes, pathologic findings, and
prognostic factors.
Patients and methods
Study population
A total of 165 patients with PTC (mean age:
46.89 6 13.22 years) and 172 control subjects (mean
age: 45.25 6 4.89 years) were enrolled in this case-
controlled study. The subjects with PTC were recruited
among patients who were treated at the Department of
Endocrinology and Metabolism at Diskapi Teaching
and Research Hospital, Ankara, Turkey, between 2011
and 2015. Patients were followed up for a mean of
39.12 6 8.4months. Subjects with anaplastic carci-
noma, follicular carcinoma, and nodular hyperplasia
were excluded. PTC was confirmed by pathology.
Controls with thyroid disease, cancer, autoimmune dis-
ease, and severe disease or family history of thyroid
carcinoma were excluded. The histopathologic features
of thyroid carcinoma were assessed according to tumor
size (T), tumor-node-metastasis (TNM) cancer staging,
uni-/multi-focal tumor, extra-thyroidal invasion, lymph
node metastasis (N), distance metastasis (M), and
angiolymphatic invasion. The clinical features of sub-
jects with thyroid carcinoma were assessed according
to treatment with/without radioactive iodine treatment.
TNM cancer staging and outcomes (disease-free and
recurrent/persistent) were assessed according to the
American Thyroid Association (ATA) guideline.17
Clinical follow-up was examined in all patients and
outcomes were classified according to disease status.
Disease-free survival was defined as negative radiologic
examination with a serum thyroglobulin value
\1mg/L and undetectable thyroglobulin antibodies
(\40 IU/L). Patients without these criteria were
defined as having persistent disease. Tumor recurrence
was defined as reappearance of tumor after complete
cure. Each subject gave written informed consent. The
study was approved by the local ethics committee of
Diskapi Teaching and Research Hospital (2015/28).
Genotype analysis
Genotyping of VDR gene single-nucleotide polymorph-
isms (SNPs) FokI (rs2228570), BsmI (rs1544410), ApaI
(rs7975232), and TaqI (rs731236) were performed.
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Genomic DNA was isolated from collected peripheral
blood samples of the subjects using a DNA Isolation
Kit (Roche Diagnostics, Indianapolis, IN, USA).
VDR polymorphisms were evaluated using reverse
transcription-polymerase chain reaction (RT-PCR).
VDR gene SNPs were separately assessed using a
fluorescence-based allele-specific PCR assay, KASPar
(KBiosciences, Hoddesdon, UK), performed on a
Rotor-Gene Q real-time cycler (Qiagen, Hilden,
Germany). Allele discrimination was performed using
Rotor-Gene Q software v.2.3.1 (Qiagen, Hilden,
Germany). The genotype identification was performed
blind without information on the phenotypes of the
subjects.
Statistical analysis
Statistical analysis was performed using the SPSS 18.0
(SPSS, Inc.) software. Variables are presented as
mean 6 standard deviation (SD) or median (min–
max), percentages (%), odds ratios (OR), and 95%
confidence intervals (CIs). Normality was tested using
the Kolmogorov–Smirnov and Shapiro–Wilk W test.
SNPs are expressed as allelic frequency (q) or preva-
lence of genotypes (%). Categorical variables were
analyzed using the chi-square test or Fisher’s exact
test, where appropriate. Student’s t-test was used for
normally distributed continuous variables or log-
transformed variables between two groups. The
Hardy–Weinberg equilibrium (HWE) at individual
loci was assessed using the chi-square test. Multiple
logistic regression analysis and Fisher’s exact test were
tested using models: dominant (major allele homozy-
gotes vs heterozygotes + minor allele homozygotes),
recessive (major allele homozygotes + heterozygotes
vs minor allele homozygotes), and codominant (major
allele homozygotes vs heterozygote and minor allele
homozygotes vs major allele homozygotes). Statistical
significance was defined as p value \0.05. Pairwise
linkage disequilibrium (LD) and correlation coeffi-
cients (r2) were analyzed using the HAPLOVIEW pro-
gram. We made a variable reflecting all possible
combinations of BsmI-ApaI-TaqI genotypes for each
SNP.
Results
Age (46.89 6 13.22 vs 45.25 6 4.89 years) and sex
(women, 81.2% vs 86.8%) did not differ between the
patients with PTC and controls (p. 0.05; Table 1).
25(OH)D3 levels were lower in patients with PTC than
in controls (14.41 6 8.10 vs 17.47 6 10.32 ng/mL,
p=0.005). Four polymorphisms of the VDR gene were
HWE in the control group. Minor allele frequency and
HWE are shown in Table 2. Distributions of VDR gene
polymorphisms are shown in Table 3. Frequency of
VDR gene ApaI rs7975232, TaqI rs731236, and BsmI
rs1544410 polymorphisms did not differ between
patients with PTC and controls in a codominant model
and dominant model and recessive model (p. 0.05,
each). VDR gene polymorphisms ApaI, TaqI, and BsmI
were not associated with PTC. Frequency of VDR gene
FokI rs2228570 increased in PTC patients than in con-
trol (p\ 0.05). Haploview analysis shows that VDR
gene polymorphisms are not in LD. Compared to con-
trol, FokI TT genotype increased in patients with PTC
in a recessive model (TT vs CT/CC, OR=1.80, 95%
CI=1.05–3.20, p=0.041) and FokI CT/TT genotype
increased in patients with PTC in a dominant model
(CT/TT vs CC, OR=1.88, 95% CI=1.20–2.96,
p=0.006). Compared to control, FokI CT and FokI
TT genotypes increased in patients with PTC in a codo-
minant model (CT vs CC, OR=1.71, 95% CI=1.15–
2.76, p=0.028 and TT vs CC, OR=2.44, 95%
CI=1.29–4.62, p=0.005).
Association between VDR gene FokI rs2228570 and
clinical features of PTC patients are shown in Table 4.
Patients carrying FokI TT genotype increased risk for
developing T3 and T4 PTC compared to patients carry-
ing FokI CC genotype (TT vs CC: OR=2.71, 95%
CI=1.13–6.53, p=0.003) and C allele and CC geno-
type (TT vs CT/CC: OR=3.21, 95% CI=1.76–6.09,
p=0.001, recessive model). The FokI T allele and TT
genotype increased risk for developing N1 PTC in wild
comparison, dominant and recessive model (TT vs CC:
OR=5.16, 95% CI: 1.31–10.42; p\ 0.001 and CT/TT
vs CC: OR=4.71, 95% CI: 1.25–12.51, p=0.008; and
TT vs CT/CC: OR=5.14, 95% CI: 2.16–10.59; p
\ 0.001, respectively). Patients carrying the FokI TT
genotype had increased risk for developing stage III/IV
PTC compared with patients carrying the CC genotype
(TT vs CC: OR=4.33, 95% CI: 1.07–10.74;
p=0.029) and C allele and CC genotype (TT vs CT/
CC: OR=2.67, 95% CI: 1.04–6.83; p=0.036, reces-
sive model). FokI T allele and TT genotype increased
risk of multifocal tumor in wild, heterozygote compari-
son, dominant and recessive model (TT vs CC:
OR=5.20, 95% CI=1.93–11.94; p=0.001; CT vs
CC: OR=2.72, 95% CI=1.25–5.93, p=0.010; CT/
TT vs CC: OR=2.26, 95% CI=1.30–3.76, p=0.002;
TT vs CT/CC: OR=2.55, 95% CI=1.03–5.93,
p=0.026; respectively). The FokI T allele and TT gen-
otype were more frequent in patients with PTC with
tumors ø 10mm in size compared with tumors
\10mm in size (TT vs CC: OR=4.09, 95%
CI=1.58–10.52, p=0.003; CT vs CC: OR=2.38,
95% CI=1.10–5.15, p=0.026; CT/TT vs CC:
OR=2.58, 95% CI=1.25–5.33, dominant model).
The FokI TT genotype was more common in patients
with PTC with extra-thyroidal invasion compared with
those without extra-thyroidal invasion (TT vs CC:
OR=15.26, 95% CI=1.90–30.98; TT vs CT/CC:
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OR=2.4, 95% CI=1.20–4.85, p\ 0.001, recessive
model). The FokI TT genotype and T allele were more
frequent in patients with PTC treated with radioiodine
therapy compared with those without radioiodine ther-
apy (TT vs CT: OR=3.15, 95% CI=1.20–8.27,
p=0.016; TT vs CC: OR=7.2, 95% CI=1.71–21.34,
p=0.002; CT/TT vs CC: OR=5.10, 95% CI=1.99–
8.28, dominant model; TT vs CT/CC: OR=4.34, 95%
CI=1.22–9.48, p=0.007, recessive model). Patients
with recurrent/persistent disease and disease-free status
did not differ between the FokI genotypes (p. 0.05).
The VDR gene polymorphisms ApaI, BsmI, and TaqI
were not related to pathologic features (multifocality,
capsule invasion, extra-thyroidal invasion, TNM-sta-
ging, tumor size, lymph node metastasis), radioiodine
therapy, and outcome.
Table 1. Characteristics of subjects.
PTC (n = 165) Control (n = 172) p
Age (years)a 46.89 6 13.22 45.25 6 4.89 0.308
Women (%) 81.2 86.6 0.175
Family history of thyroid cancer (%) 4.9 –
Preoperative 25(OH)D (ng/mL)a 14.41 6 8.10 17.47 6 10.32 0.005
Age at the diagnosis (years)a 44.70 6 13.55 –
Type (%)
Conventional papillary thyroid cancer 63.6
Follicular variant of papillary thyroid cancer 32.7
T classification (%)
Tx 4.8
T1 and T2 78.2
T3 and T4 17.0
N classification (%)
Nx 4.8
N0 78.8–78.2
N1 16.4–17.0
M classification (%)
M1 1.3
M0 98.7
Clinical stage (%)
I and II 85.4
III and IV 14.6
Multifocal (%) 56.8
Cancer size ø 1 cm (%) 54.1
Extra-thyroidal invasion (%) 9.6
Cervical lymph node metastasis (%) 17.2
Distance metastasis (%) 1.8
Capsular invasion (%) 14.7
Angiolymphatic invasion (%) 8.3
Perineural invasion (%) 1.9
I131 radiotherapy (%) 86.1
Time of follow-up (months)a 39.12 6 8.4
Disease free (%) 89.1
Recurrent/persistent (%) 7.9
PTC: papillary thyroid cancer; T: tumor size; N: lymph node metastasis; M: distance metastasis; 25(OH)D: 25-hydroxy-vitamin D.
Bold value represents significant p-value.
aData are presented as mean 6 SD. Percentage was shown as (%).
Table 2. Minor allele frequency and Hardy–Weinberg equilibrium of VDR gene polymorphisms.
Risk allele MAF for study sample p for HWE in control
ApaI rs7975232 C 0.41 0.110
TaqI rs731236 C 0.36 0.122
BsmI rs15444410 G 0.39 0.138
FokI rs2228570 T 0.40 0.269
MAF: minor allele frequency; HWE: Hardy–Weinberg equilibrium.
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Table3. Genotype analysis of VDR gene polymorphisms.
Control (%) PTC (%) OR (95% CI) p
ApaI rs7975232
Codominant wild-type AA 30.8 32.7
Heterozygous AC 54.1 57.6 1.00 (0.62–1.61) 0.991
Homozygous CC 15.1 9.7 0.60 (0.29–1.25) 0.173
Dominant (AA/AC+CC) 30.8/69.2 32.7/67.3 0.91 (0.57–1.44) 0.706
Recessive (AA+AC/CC) 84.9/15.1 90.3/9.7 0.63 (0.31–1.17) 0.132
TaqI rs731236
Codominant wild-type TT 40.1 37.0
Heterozygous CT 50.6 50.9 1.09 (0.69–1.72) 0.705
Homozygous CC 9.3 12.1 1.41 (0.67–2.97) 0.359
Dominant (TT/CT+CC) 40.1/59.9 37.0/63.0 1.14 (0.73–1.77) 0.553
Recessive (TT+CT/CC) 90.7/9.3 87.9/12.1 1.34 (0.67–2.69) 0.402
BsmI rs1544410
Codominant wild-type AA 36.0 30.3
Heterozygous AG 52.3 55.2 1.25 (0.78–2.01) 0.348
Homozygous GG 11.6 14.5 1.48 (0.73–2.99) 0.265
Dominant (AA/AG+GG) 36.0/64.0 30.3/69.7 1.18 (0.82–2.04) 0.263
Recessive (AA+AG/GG) 88.4/11.6 85.5/14.5 1.29 (0.68–2.44) 0.427
FokI rs2228570
Codominant wild-type CC 43.6 29.1–28.5
Heterozygous CT 43.0 49.1–49.1 1.71 (1.15–2.76) 0.028
Homozygous TT 13.4 21.8–22.4 2.44 (1.29–4.62) 0.005
Dominant (CC/CT+TT) 43.6/56.4 29.1/70.9 1.88 (1.20–2.96) 0.006
Recessive (CC+CT/TT) 86.6/13.4 78.2/21.8 1.80 (1.05–3.20) 0.041
PTC: papillary thyroid cancer; OR: odds ratio; CI: confidence interval.
Bold values represent significant p-values.
Table 4. Associations between VDR gene FokI polymorphism and clinical feature of papillary thyroid cancer.
Variables Dominant model Recessive model
Genotype (CT+TT/CC) (CC+CT/TT)
CC (wild) CT TT p p OR (95% CI) p OR (95% CI) p
n = 47 n= 81 n = 37 CT/CC TT/CC
T classification (n)
T1 and T2 39 68 22
T3 and T4 4 11 13 0.458 0.003 2.60 (0.84–7.99) 0.086 3.21 (1.76–6.09) 0.001
N classification (n)
N0 40 67 22
N1 2 12 14 0.088 \0.001 4.71 (1.25–12.51) 0.008 5.14 (2.16–10.59) \0.001
Clinical stage (n)
I and II 39 68 27
III and IV 3 11 9 0.250 0.029 2.28 (0.77–4.78) 0.095 2.67 (1.04–6.83) 0.036
Multifocal (n) 15 47 26 0.010 0.001 2.26 (1.30–3.76) 0.002 2.55 (1.03–5.93) 0.026
Cancer size ø 1 cm (n) 15 45 25 0.026 0.003 2.58 (1.25–5.33) 0.009 2.18 (0.98–4.84) 0.052
Extra-thyroidal invasion (n) 1 4 10 0.458 0.001 4.46 (0.66–20.1) 0.057 2.4 (1.20–4.85) \0.001
Angiolymphatic invasion (n) 1 5 7 0.322 0.010 3.81 (0.57–12.53) 0.094 1.73 (0.96–3.15) 0.005
Recurrent/persistent (n) 1 5 7 0.335 0.065 3.81 (0.57–12.56) 0.095 4.74 (1.48–11.15) 0.062
I131 radiotherapy (n) 30 71 35 0.016 0.002 5.10 (1.99–8.28) 0.001 4.34 (1.22–9.48) 0.007
OR: odds ratio; CI: confidence interval; T: tumor size; N: lymph node metastasis.
The number of subjects is shown as (n).
Bold values represent significant p-values.
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Discussion
This is the first study to show the effects of VDR gene
polymorphisms on the clinical features of PTC includ-
ing TNM cancer staging, outcomes, pathologic find-
ings, and prognostic factors in a Turkish population.
We found that the frequency of VDR gene ApaI, TaqI,
and BsmI polymorphisms did not differ between PTC
and controls with no association. The frequency of
VDR gene FokI TT genotype and CT heterozygotes
were increased in PTC compared with the controls.
VDR gene FokI was associated with an increased risk
of PTC. Haploview analysis showed that VDR gene
polymorphisms were not in LD. Patients with PTC car-
rying the FokI TT genotype were more likely to have
adverse pathologic and prognostic factors including T3
and T4, stage III/IV, and extra-thyroidal invasion.
Patients with PTC carrying the FokI CT/TT or TT gen-
otype were more likely to develop N1, multifocal
tumor, and tumors ø 10mm. FokI CT/TT or TT geno-
type carriers were more likely to be treated with radio-
iodine therapy. VDR gene FokI was related to
aggressiveness of PTC disease; however, it was not cor-
related with persistence/recurrence. Thus, VDR gene
FokI might be used as a biomarker for poor clinico-
pathologic findings.
In humans, vitamin D shows a supportive effect on
thyroid tissue. VDR gene BsmI and TaqI polymorph-
isms were shown to be associated with decreased risk
of autoimmune thyroid disease.18VDR gene ApaI,
Bsml, and FokI polymorphisms were associated with
Graves’ disease in an Asian population, whereas ApaI,
Bsml, TaqI, and FokI were not associated with Graves’
disease in Caucasians.19TaqI CC and FokI TT were
increased in Hashimoto’s thyroiditis in Turkey.20
Genetic and epigenetic determinants of thyroid cancer
may have an effect on 1,25(OH)2D3 signaling.
Development and progression of thyroid cancer
depends on impaired 1,25(OH)2D3 signaling
21,22 which
has been confirmed in clinical studies22–26 and thyroid
cancer cell lines.27 Local 1,25(OH)2D3-VDR signaling
is decreased in primary thyroid cancer with local lymph
node metastasis, and complete loss of signaling is more
significant in anaplastic thyroid cancer with distant
metastasis.10,22–25 Hence, thyroid cancer progression is
characterized by the loss of proteins that play a role in
vitamin D signaling or 1,25(OH)2D3 sensitivity.
27 The
signaling effect of 1,25(OH)2D3-VDR in thyroid cancer
occurs via the local anti-tumoral effect of
1,25(OH)2D3.
21,22 This anti-tumoral effect occurs either
directly (via VDR binding) or indirectly (via the inter-
action between other critical transcriptional regulators
or cell signaling systems).21,28,29 Therapeutic use of
vitamin D agonists in thyroid cancer requires the pres-
ence of VDR. An experimental study showed that
VDR FokI CC was associated with vitamin D analog
resistance in the treatment of thyroid cancer.30 Active
vitamin D has many anti-cancer features including
anti-proliferative, anti-apoptotic, pro-differentiating,
and anti-inflammatory effects.5–10 These effects are
mediated by VDR. VDR regulates also metabolic path-
ways such as the immune response and cancer signal-
ing.5–8 VDR is stimulated by p53, a tumor-suppressing
gene.16 An association was found between vitamin D
deficiency and thyroid cancer.10,31,32
Epidemiologic studies reported that there was a rela-
tionship between VDR gene and breast cancer, prostate
cancer, lung cancer, colorectal cancer, and other gas-
trointestinal cancers.4–8 However, reliable data on thyr-
oid cancer are available only in in vitro experimental
studies.10,23,24,27–31VDR gene Apa, Bsml, Taq, and FokI
genotypes were not associated with risk of PTC in a
German population.10 In an Iranian population, fre-
quency of VDR gene ApaI, FokI, Bsml, Taq, and Tru9
did not differ between differentiated thyroid cancer and
controls, with no relationship.16 However, these studies
did not investigate the genotype-phenotype correlation
such as TNM cancer staging, outcomes, pathologic
findings, and prognostic factors. In this study, vitamin
D deficiency was found in patients with PTC compared
with controls. This study showed that frequency of
VDR gene ApaI, TaqI, and BsmI did not differ between
patients with PTC and controls. VDR gene ApaI, TaqI,
and BsmI were not associated with a risk for PTC.
VDR gene FokI rs2228570 showed significant differ-
ences between patients with PTC and controls: VDR
gene FokI (variant or heterozygotes) compared with
wild type (CC) revealed a significant association. VDR
gene FokI TT (TT vs CC: OR=2.44, 95% CI=1.29–
4.62, p=0.005) and CT heterozygotes (CT vs CC:
OR=1.71, 95% CI=1.15–2.76, p=0.028) were asso-
ciated with an increased PTC risk compared with the
controls. Our study suggests that VDR gene FokI may
be associated with the development of PTC. Allele fre-
quency distribution showed a significant association of
FokI variant allele (T) on susceptibility to PTC. These
results revealed that VDR gene FokI might play a criti-
cal role in the etiology of the PTC. VDR gene FokI TT
genotype was associated with having T3 and T4, stage
III/IV, and extra-thyroidal invasion of PTC. FokI CT/
TT or TT genotype was associated with developing N1,
multifocality, and tumor size ø 10mm in PTC.
Patients carrying FokI CT/TT or TT genotype were
mostly treated with radioiodine therapy. The persis-
tence/recurrence rate in PTC did not differ between
FokI genotypes. Although VDR gene FokI was associ-
ated with more advanced TNM stage, greater diameter
of tumor, multifocality, and extra-thyroidal invasion,
outcomes in follow-up did not differ. VDR gene FokI
might be considered as a risk for poor clinicopathologic
features and advanced stage of PTC. VDR gene FokI
might be suggested as a poor prognostic factor of PTC.
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However, the molecular mechanism needs to be
identified.
Bsml, ApaI, and TaqI polymorphisms of VDR gene
are found in the three primer untranslated region (3#-
UTR) and have been shown to be in strong
LD.33,34FokI polymorphism was reported as an inde-
pendent marker of VDR gene because it has not been
shown to be in LD with any other VDR polymorph-
isms.34 Haploview analysis showed that VDR gene
polymorphisms were not in LD. ApaI and BsmI poly-
morphisms of the VDR gene, both in intron 8, are con-
sidered as silent SNPs. These polymorphisms do not
change the amino acid sequence of the encoded protein,
but they might affect gene expression by modulating
stability of messenger RNA (mRNA).11TaqI poly-
morphism is located at codon 352 in exon 9 of the
VDR gene. According to the Taq restriction site, prod-
ucts are digested into two or three fragments. TT geno-
type (absence of restriction site) is related to lower
active vitamin D3.4–11 The only locus that has an
impact on the structure of VDR protein is the FokI
polymorphism, which is located on the 5# end region of
VDR gene. VDR gene FokI polymorphism is functional
because it is found in a coding sequence. FokI poly-
morphism is located in the first ATG starting code of
VDR protein. FokI is involved in thymine to cytosine
(T/C) substitution at exon 2, the first translation initia-
tion region is removed, and the transcriptional activity
of VDR is changed.4–11,16 It alters the ACG codon that
is found 10 base pairs upstream from the translation
starting codon and leads to generating an additional
starting codon. Two different VDR isoforms occur
with the transition of allele T to C in ATG. When the
initiating translation starts from this alternative site in
the thymine variant, it leads to the generation of a lon-
ger VDR protein comprising 427 amino acids. The gene
is transcribed in normal length if there is a restriction
site. Thus, the C/C allele codes the 424-amino acid pro-
tein and the T/T allele codes the 427-amino acid pro-
tein. The longer VDR protein has low activity in
transcription; accordingly, activation is decreased in
the target cell.4–11 Arai et al.35 reported that compared
with FokI T/T genotype, FokI C/C showed 1.7-fold
greater function in vitamin D-dependent transcrip-
tional activation of a reporter through the regulation of
a vitamin D response element. FokI rs2228570 poly-
morphism is the only VDR gene polymorphism
involved in the generation of an altered protein
expression.11
In this study, the control population was consistent
with HWE. The small sample size, cross-sectional
design, and seasonal change in 25(OH)D3 are limita-
tions of this study.
In conclusion, this study showed that VDR gene
FokI might contribute to the susceptibility of PTC risk
in the Turkish population. VDR gene FokI correlated
with aggressiveness of papillary thyroid cancer but not
with outcome of disease. FokI could be useful as supple-
mentary prognostic factor to assess high risk of papil-
lary thyroid cancer and to identify patients who need
more aggressive management and follow-up. Further
studies in different populations are needed to confirm
these results.
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